Key result
Sacubitril/valsartan treatment was associated with significant improvements in LVEF, LV end-systolic volume, and functional class versus baseline, particularly in patients with disease duration <8.5 years.
Why the study?
Sacubitril/valsartan is recommended for heart failure with reduced ejection fraction, but whether its cardiac remodeling effects correlate with heart failure duration remained unclear.
Does sacubitril/valsartan improve cardiac remodeling in patients with heart failure, and does this effect depend on disease duration?
Cohort (n=69)
Does sacubitril/valsartan improve cardiac remodeling in patients with heart failure, and does this effect depend on disease duration?
Sacubitril/valsartan induces favorable cardiac remodeling primarily in heart failure patients with a shorter disease duration (<8.5 years).
Answers are grounded in this paper and cite their sources.
May support earlier sacubitril/valsartan use in HF but should not change practice; leaves open prospective trials by disease duration.
AIMS: The angiotensin receptor and neprilysin inhibitor (ARNI) sacubitril/valsartan (LCZ696) is recommended for the treatment of patients with heart failure in New York Heart Association (NYHA) class II-III and left ventricular ejection fraction (LVEF) 35% or less. We examined the effects of sacubitril/valsartan on cardiac remodeling and their correlation with heart failure duration in patients enrolled in our heart failure clinic from March 2017 to December 2019. METHODS: Echocardiographic and clinical/laboratory data were collected at baseline and at 6-month and 12-month follow-up visits in 69 patients (age 67 ± 12 years, disease duration 8.4 ± 5.8 years, 93% men). RESULTS: At both time points, mean NYHA class, NT-proBNP level, LVEF, LV end-systolic volume, and estimated systolic pulmonary pressure significantly (P < 0.05) improved versus baseline, as did the proportion of patients with diastolic dysfunction grade 3 or functional mitral regurgitation grade 3-4. In the subgroup with mean disease duration less than 8.5 years (n = 40), there was a significant improvement in all variables at both time points; in this group, a recovery of right ventricular function was also seen at the 12-month follow-up. On the contrary, patients with heart failure duration of at least 8.5 years (n = 29) showed only a slight improvement in LVEF and mitral regurgitation at 12 months. There were no significant changes in renal function and/or potassium levels in all patients. CONCLUSION: In patients with a relatively short disease duration, sacubitril/valsartan was associated with a strong favorable remodeling of the left ventricle and improvement in pulmonary circulation.
No takes yet. Share an insight, caveat, or question.
Villani et al. (2020) conducted a cohort in Heart failure (n=69). Sacubitril/valsartan vs. Baseline was evaluated on Changes in NYHA class, NT-proBNP level, LVEF, LV end-systolic volume, and estimated systolic pulmonary pressure (p=<0.05). Sacubitril/valsartan treatment was associated with significant improvements in LVEF, LV end-systolic volume, and functional class versus baseline, particularly in patients with disease duration <8.5 years.
Synapse has enriched 10 related papers. Consider them for comparative context: